A layer of mucus cover on the gastrointestinal epithelium forms a physical and firm barrier to prevent the invasion of pathogens in our gut [
54]. Goblet cells produce mucins (MUC) continuously in normal physiological circumstances; however, gut toxins, inflammatory cytokines, microbiome and microbial metabolites modify this process positively or negatively [
59]. Some inflammatory molecules like TNFα, IL-1β and IL-6 are the main regulators of mucin exocytosis and synthesis [
60]. It has been known that IL-6 promotes the expression of the secreted gel-forming mucins (MUC5AC, MUC2, MUC6 and MUC5B) [
61‐
63]. The prominent secreted gel-forming mucin in the small and large intestine is Mucin2 (MUC2). MUC2 is an important protective barrier against external pathogens, and it has diverse functions in intestinal homeostasis [
64]. The mucus layer serves as an energy provider for gut microbiome. Moreover, it also serves as a matrix for commensal microbiome colonization and attachment, which prevents pathogenic bacteria from growing/binding within the mucus [
65]. Currently, the capability of microbiota to degrade MUC2 has been thought of as a pathogenicity factor. Pathogens, including enterotoxigenic
E. coli, could degrade MUC2 mucin through different mechanisms [
66,
67]. Besides, acute intestinal infection induces rapid mucous secretion, which may aid in eliminating pathogens. Cross talk between the intestinal microbiota and mucus layer contributes to the regulated production of mucin by goblet cells [
68]. Moreover, goblet cells are heavily influenced by interactions with the immune system. The epithelial barrier could be influenced or impaired by the damaged goblet cell, synthesis dysregulation and altered post-translational modifications when immune system changes in our gut [
69]. The impaired epithelial barrier results in translocation of bacteria and their toxic metabolites. Cell wall components like endotoxin/LPS, microbiome metabolites, such as SCFAs/D-lactate and inflammatory factors produced by immune cells infiltrate into bloodstream and induce long-distance inflammation in the IVD [
70]. For instance, SCFAs are fermented by the bacteria in the gut where they provide energy to epithelial cells and promote the activity of immune cells [
71,
72]. SCFAs have emerged as key regulatory metabolites produced by the gut microbiota.
Although many studies have evaluated the effects of prebiotic consumption on bone resorption or osteoclast formation, our understanding of how gut microbes communicate with IVD remains ill-defined [
73]. The degenerative disc is accompanied by vertebral bone remodelling, including bony endplate thickening and osteophyte formation [
74]. Calcification of the IVD has been correlated with osteoblast formation [
75]. Animal research showed reduced osteoclast numbers in C57BL/6 mice and osteoporotic mice following propionate and butyrate treatment. SCFAs promote the differentiation of naive CD4 + cells into Tregs resided preferentially on the endosteal surfaces of bone [
76]; Tregs could promote osteoblast differentiation and suppress osteoclastogenesis [
77,
78], moreover, it is also required for parathyroid hormone-stimulated (PTH-stimulated) bone formation [
79]. Besides, SCFAs have direct effects on inhibition of bone resorption or osteoclast formation either via activation of G Protein-Coupled Receptors (GPCR) or through histone deacetylase (HDAC) inhibition. Moreover, the appearance of calcium deposits in the disc and expression of the extracellular calcium-sensing receptor (CaSR) are closely related to the GPCR in the degenerated discs [
80], which means that the diffusion of gut-derived SCFAs into the IVDs can therefore lead to calcification and IDD. SCFAs can also induce pro-inflammatory phenotypes of immune cells in the IVD and lead to the pathogenesis of neuropathic pain.